MAPK14 and chronic obstructive pulmonary disease: Inhaled p38 inhibitors also have potential and may represent a means to limit systemic side-effects of treatment [19, 20] and are also in clinical trials for COPD (ClinicalTrials.gov identifier: NCT00642148) and could limit systemic side-effects of treatment.